More Than Shyness

Social anxiety disorder is not a personality quirk. It is a condition in which the brain’s threat detection system overreacts to social situations, producing a fear response that is wildly out of proportion to any actual danger. The person knows, intellectually, that giving a presentation at work is unlikely to result in catastrophe. But their amygdala does not agree, and the amygdala does not take direction well.

The experience goes beyond nervousness. People with social anxiety disorder describe a specific and exhausting cycle: anticipatory dread in the hours or days before a social event, intense physiological distress during the event (racing heart, sweating, trembling, difficulty forming sentences), and prolonged post-event rumination in which they replay every interaction and conclude they humiliated themselves. Over time, avoidance becomes the dominant strategy. You stop accepting invitations. You turn down promotions that require public speaking. You eat lunch alone because the break room feels like a minefield.

This is not rare. Social anxiety disorder is the third most common psychiatric condition in the United States, behind major depression and alcohol use disorder. It affects approximately 15 million American adults. And it tends to start early—median onset is age 13—which means many people have spent decades building their lives around the avoidance.

Why Standard Treatments Leave a Gap

The first-line treatments for social anxiety disorder are SSRIs (like sertraline or paroxetine) and cognitive behavioral therapy (CBT), specifically a form called exposure therapy. Both have a meaningful evidence base. The problem is the response rates.

In clinical trials, remission rates for social anxiety disorder with SSRIs hover between 25% and 35%. That means two out of three patients on a properly dosed SSRI still have clinically significant social anxiety after an adequate trial. SSRIs also take 4 to 8 weeks to reach full effect for anxiety, and the anxiety often worsens during the first two weeks of treatment before it improves.

CBT response rates are somewhat higher—around 50–60% for quality exposure-based protocols—but access is a real constraint. Finding a therapist trained in exposure therapy for social anxiety, who has openings, who accepts your insurance, and who is located within a reasonable distance is a significant ask. Wait times of months are common.

Benzodiazepines provide rapid relief but carry dependency risk and cognitive impairment with long-term use. They are generally not recommended as ongoing treatment for social anxiety, and they can paradoxically interfere with exposure therapy by preventing the emotional processing that makes exposure effective.

For the 30–40% of patients who have tried SSRIs, attempted therapy, possibly tried an SNRI or buspirone, and still cannot eat in a restaurant without distress—the options become thin. This is where the ketamine research begins to matter.

The Landmark Trial

In 2018, researchers at the Yale School of Medicine and the National Institute of Mental Health published the first double-blind, placebo-controlled study of ketamine specifically for social anxiety disorder in Neuropsychopharmacology.

The design was rigorous. Eighteen adults with a primary diagnosis of social anxiety disorder (not generalized anxiety, not depression with social features, but diagnosed social anxiety as the main condition) received both a ketamine infusion (0.5 mg/kg over 40 minutes) and a placebo infusion (normal saline) in random order, separated by a 28-day washout period. Neither the patients nor the raters knew which infusion was which.

The results:

This proof-of-concept trial provides initial evidence that ketamine may be effective in reducing anxiety in patients with social anxiety disorder. — Taylor et al., Neuropsychopharmacology, 2018

A few important caveats. The sample was small (18 participants), and the study was designed as a proof-of-concept rather than a definitive efficacy trial. But the design was among the most rigorous possible for a single-site study, and the results were statistically significant on the primary outcome measure.

The 2025 Systematic Review

In 2025, Masdrakis and colleagues published a systematic review in the Journal of Psychopharmacology examining ketamine and esketamine treatment protocols across anxiety disorders, including social anxiety disorder, PTSD, OCD, and treatment-resistant anxiety broadly.

Their conclusions were measured but meaningful. The evidence suggests that ketamine produces anxiolytic effects across anxiety disorder subtypes, with effects that can be sustained through repeated dosing and maintenance protocols. The review noted that treatment-resistant anxiety remains a significant clinical problem with limited options, and that ketamine represents one of the few pharmacological approaches with evidence for rapid onset in this population.

A separate meta-analysis of randomized controlled trials published in Therapeutic Advances in Psychopharmacology found that ketamine demonstrated preliminary efficacy across treatment-resistant anxiety spectrum disorders, with fast-acting anxiolytic effects lasting approximately one to two weeks after a single dose.

Additional evidence comes from a February 2026 preclinical study that found ketamine reduced anxiety-related behavior and social withdrawal in mice that had experienced chronic social stress during adolescence. The researchers demonstrated that ketamine restored function in brain circuits disrupted by social stress, suggesting the drug addresses the neurobiological consequences of prolonged social threat exposure rather than simply sedating the anxiety response.

The Neuroscience of Social Fear

Understanding why ketamine helps social anxiety requires understanding what goes wrong in the brain during social threat processing.

In social anxiety disorder, the amygdala—the brain’s threat detection center—shows exaggerated reactivity to social cues. Functional MRI studies consistently find that people with social anxiety show heightened amygdala activation in response to angry faces, critical facial expressions, and even neutral faces that the brain interprets as potentially judging. The amygdala fires as though a social interaction is genuinely dangerous.

Normally, the prefrontal cortex provides top-down regulation of amygdala activity. It assesses context, applies reasoning, and modulates the fear response when the situation does not actually warrant it. In social anxiety disorder, this prefrontal regulation is weakened. Glutamatergic projections from the medial prefrontal cortex to the amygdala—the pathways that should be saying “this is a meeting, not a threat”—are less effective.

This creates a specific neurobiological deficit: the amygdala overreacts, and the prefrontal cortex cannot adequately rein it in. The person experiences fear that their rational mind knows is disproportionate, but knowing does not stop the feeling. The cognitive understanding and the emotional experience are being generated by different brain circuits, and the emotional circuit is winning.

Ketamine’s mechanism addresses this at the synaptic level. NMDA receptor blockade triggers a cascade that increases BDNF release, activates mTOR signaling, and promotes rapid synaptogenesis—the formation of new synaptic connections. In the context of social anxiety, this means:

Social Anxiety Is Not Just Anxiety

We already have an article on ketamine for anxiety broadly, so it is worth explaining why social anxiety warrants its own discussion.

Generalized anxiety disorder involves chronic, diffuse worry across many life domains. Social anxiety disorder involves specific, intense fear centered on social evaluation. The physiological responses overlap (rapid heartbeat, sweating, muscle tension), but the cognitive architecture is different. Social anxiety is defined by:

This avoidance is the most clinically significant feature. A person with generalized anxiety may worry about many things but still participate in their life. A person with severe social anxiety may have restructured their entire existence to minimize social exposure, and the longer avoidance persists, the more the brain consolidates the belief that social situations are dangerous.

The Neuroplastic Window and Exposure

This is where ketamine’s neuroplastic effects become particularly relevant for social anxiety. The neuroplastic window—the 24 to 72 hours of enhanced synaptic flexibility following a ketamine infusion—creates a period in which the brain is more receptive to forming new associations and revising old ones.

For social anxiety specifically, this window creates an opportunity for something that is usually very difficult: approaching social situations while the fear response is dampened and the prefrontal cortex is better equipped to regulate it. A patient who has avoided phone calls for years might find, in the days after an infusion, that calling to make an appointment feels possible. Someone who has eaten alone for months might sit in the break room. These are small acts, but they generate experiential data that directly contradicts the catastrophic predictions the social anxiety has been running.

Several of our patients with anxiety describe the post-infusion period not as a removal of anxiety but as a reduction in its authority. The anxious thought still arises, but it does not commandeer the entire nervous system. There is space between the thought and the response, and in that space, a different choice becomes available.

If you are working with a therapist who does exposure-based CBT, the neuroplastic window may be an ideal time to schedule exposure exercises. The combination of pharmacological support (ketamine reducing amygdala hyperreactivity and enhancing prefrontal regulation) and behavioral intervention (exposure generating corrective learning) may be more effective than either approach alone. This is an area of active research interest, and we are optimistic about what future studies will show.

What Treatment Looks Like at Our Clinic

At Music City Ketamine, we treat social anxiety as part of our broader anxiety protocol. During your initial consultation, we discuss your specific symptom profile: what situations trigger the most distress, how much avoidance has narrowed your daily life, what treatments you have tried, and how your social anxiety interacts with any other conditions you carry (depression, PTSD, and social anxiety frequently coexist).

Marla Peterson, CRNA, administers and monitors every session. The infusion protocol for anxiety follows the standard 0.5 mg/kg dosing over 40 minutes, consistent with the clinical trial evidence. We typically begin with a series of six infusions over two to three weeks, with response assessed along the way.

What patients with social anxiety often describe after the initial sessions is subtle but real: a sense of the world being less threatening. The inner monologue of self-critique quiets somewhat. Eye contact feels less loaded. Conversations feel less like performances being graded.

Walter White and Wilma, our therapy dogs, are often present during sessions. For patients with social anxiety, the uncomplicated warmth of a dog who wants nothing from you beyond proximity can be grounding in a particular way. Dogs do not evaluate. They do not judge your word choice or notice that your hands were shaking. For some patients, interacting with the dogs during treatment is the first social interaction in a long time that carries no threat of judgment.

Maintenance protocols are individualized. Some patients sustain improvement for weeks between sessions; others benefit from monthly or bimonthly infusions. We track your response and adjust based on how your symptoms evolve. For patients in the Franklin, Nashville, Brentwood, and Middle Tennessee area, our clinic is located at 480 Duke Dr., Suite #100 in Franklin. Information about pricing is available on our website.